Physician profile
Sara Goodwin
NPI 1013764984
$467.32
in general payments reported to CMS, 2019-2025
12 companies · $415 in 2025
The $415 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $52.36 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $467.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $125.18 | 2025 | Spravato |
| Lilly USA, LLC | $70.35 | 2024-2025 | Zepbound, Mounjaro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $62.38 | 2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $37.41 | 2024 | Fruzaqla, Trintellix |
| Abbvie INC. | $34.03 | 2025 | |
| Novo Nordisk INC | $33.88 | 2025 | Wegovy |
| Astellas Pharma US INC | $26.85 | 2025 | Veozah |
| Sumitomo Pharma America, INC. | $17.07 | 2025 | Gemtesa |
| Abbott Laboratories | $17.03 | 2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $14.99 | 2025 | Airsupra |
| Pfizer INC. | $14.30 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.85 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Goodwin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.